In support of this concept, we used genomewide profiling of hormone‐treated breast cancer PDEs to capture ERα binding events and demonstrated reprogramming of ERα binding by synthetic progestin R5020, a phenomenon we recently reported using cell line models and clinical samples (Mohammed et al., 2015; Singhal et al., 2016). The gene discussed is ESR1; the disease is breast cancer.